Cargando…
Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer
Despite significant advances in breast imaging, the ability to accurately detect Breast Cancer (BC) remains a challenge. With the discovery of key biomarkers and protein signatures for BC, proteomic technologies are currently poised to serve as an ideal diagnostic adjunct to imaging. Research studie...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980010/ https://www.ncbi.nlm.nih.gov/pubmed/27508384 http://dx.doi.org/10.1371/journal.pone.0157692 |
_version_ | 1782447412126679040 |
---|---|
author | Henderson, Meredith C. Hollingsworth, Alan B. Gordon, Kelly Silver, Michael Mulpuri, Rao Letsios, Elias Reese, David E. |
author_facet | Henderson, Meredith C. Hollingsworth, Alan B. Gordon, Kelly Silver, Michael Mulpuri, Rao Letsios, Elias Reese, David E. |
author_sort | Henderson, Meredith C. |
collection | PubMed |
description | Despite significant advances in breast imaging, the ability to accurately detect Breast Cancer (BC) remains a challenge. With the discovery of key biomarkers and protein signatures for BC, proteomic technologies are currently poised to serve as an ideal diagnostic adjunct to imaging. Research studies have shown that breast tumors are associated with systemic changes in levels of both serum protein biomarkers (SPB) and tumor associated autoantibodies (TAAb). However, the independent contribution of SPB and TAAb expression data for identifying BC relative to a combinatorial SPB and TAAb approach has not been fully investigated. This study evaluates these contributions using a retrospective cohort of pre-biopsy serum samples with known clinical outcomes collected from a single site, thus minimizing potential site-to-site variation and enabling direct assessment of SPB and TAAb contributions to identify BC. All serum samples (n = 210) were collected prior to biopsy. These specimens were obtained from 18 participants with no evidence of breast disease (ND), 92 participants diagnosed with Benign Breast Disease (BBD) and 100 participants diagnosed with BC, including DCIS. All BBD and BC diagnoses were based on pathology results from biopsy. Statistical models were developed to differentiate BC from non-BC (i.e., BBD and ND) using expression data from SPB alone, TAAb alone, and a combination of SPB and TAAb. When SPB data was independently used for modeling, clinical sensitivity and specificity for detection of BC were 74.7% and 77.0%, respectively. When TAAb data was independently used, clinical sensitivity and specificity for detection of BC were 72.2% and 70.8%, respectively. When modeling integrated data from both SPB and TAAb, the clinical sensitivity and specificity for detection of BC improved to 81.0% and 78.8%, respectively. These data demonstrate the benefit of the integration of SPB and TAAb data and strongly support the further development of combinatorial proteomic approaches for detecting BC. |
format | Online Article Text |
id | pubmed-4980010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-49800102016-08-25 Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer Henderson, Meredith C. Hollingsworth, Alan B. Gordon, Kelly Silver, Michael Mulpuri, Rao Letsios, Elias Reese, David E. PLoS One Research Article Despite significant advances in breast imaging, the ability to accurately detect Breast Cancer (BC) remains a challenge. With the discovery of key biomarkers and protein signatures for BC, proteomic technologies are currently poised to serve as an ideal diagnostic adjunct to imaging. Research studies have shown that breast tumors are associated with systemic changes in levels of both serum protein biomarkers (SPB) and tumor associated autoantibodies (TAAb). However, the independent contribution of SPB and TAAb expression data for identifying BC relative to a combinatorial SPB and TAAb approach has not been fully investigated. This study evaluates these contributions using a retrospective cohort of pre-biopsy serum samples with known clinical outcomes collected from a single site, thus minimizing potential site-to-site variation and enabling direct assessment of SPB and TAAb contributions to identify BC. All serum samples (n = 210) were collected prior to biopsy. These specimens were obtained from 18 participants with no evidence of breast disease (ND), 92 participants diagnosed with Benign Breast Disease (BBD) and 100 participants diagnosed with BC, including DCIS. All BBD and BC diagnoses were based on pathology results from biopsy. Statistical models were developed to differentiate BC from non-BC (i.e., BBD and ND) using expression data from SPB alone, TAAb alone, and a combination of SPB and TAAb. When SPB data was independently used for modeling, clinical sensitivity and specificity for detection of BC were 74.7% and 77.0%, respectively. When TAAb data was independently used, clinical sensitivity and specificity for detection of BC were 72.2% and 70.8%, respectively. When modeling integrated data from both SPB and TAAb, the clinical sensitivity and specificity for detection of BC improved to 81.0% and 78.8%, respectively. These data demonstrate the benefit of the integration of SPB and TAAb data and strongly support the further development of combinatorial proteomic approaches for detecting BC. Public Library of Science 2016-08-10 /pmc/articles/PMC4980010/ /pubmed/27508384 http://dx.doi.org/10.1371/journal.pone.0157692 Text en © 2016 Henderson et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Henderson, Meredith C. Hollingsworth, Alan B. Gordon, Kelly Silver, Michael Mulpuri, Rao Letsios, Elias Reese, David E. Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer |
title | Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer |
title_full | Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer |
title_fullStr | Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer |
title_full_unstemmed | Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer |
title_short | Integration of Serum Protein Biomarker and Tumor Associated Autoantibody Expression Data Increases the Ability of a Blood-Based Proteomic Assay to Identify Breast Cancer |
title_sort | integration of serum protein biomarker and tumor associated autoantibody expression data increases the ability of a blood-based proteomic assay to identify breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980010/ https://www.ncbi.nlm.nih.gov/pubmed/27508384 http://dx.doi.org/10.1371/journal.pone.0157692 |
work_keys_str_mv | AT hendersonmeredithc integrationofserumproteinbiomarkerandtumorassociatedautoantibodyexpressiondataincreasestheabilityofabloodbasedproteomicassaytoidentifybreastcancer AT hollingsworthalanb integrationofserumproteinbiomarkerandtumorassociatedautoantibodyexpressiondataincreasestheabilityofabloodbasedproteomicassaytoidentifybreastcancer AT gordonkelly integrationofserumproteinbiomarkerandtumorassociatedautoantibodyexpressiondataincreasestheabilityofabloodbasedproteomicassaytoidentifybreastcancer AT silvermichael integrationofserumproteinbiomarkerandtumorassociatedautoantibodyexpressiondataincreasestheabilityofabloodbasedproteomicassaytoidentifybreastcancer AT mulpurirao integrationofserumproteinbiomarkerandtumorassociatedautoantibodyexpressiondataincreasestheabilityofabloodbasedproteomicassaytoidentifybreastcancer AT letsioselias integrationofserumproteinbiomarkerandtumorassociatedautoantibodyexpressiondataincreasestheabilityofabloodbasedproteomicassaytoidentifybreastcancer AT reesedavide integrationofserumproteinbiomarkerandtumorassociatedautoantibodyexpressiondataincreasestheabilityofabloodbasedproteomicassaytoidentifybreastcancer |